CARA (Cara Therapeutics Inc) רווח למניה לשנה מתגלגלת

Cara Therapeutics, Inc. (CARA) is pursuing a strategic course aimed at creating a flexible supply network of neuropreparations to combat pruritus. The EPS YoY TTM growth trajectory demonstrates progress toward this goal, with 67.50 indicating the current level. However, management restructuring and cost reductions are creating certain challenges, despite the company's stable authority among specialized researchers.
CARA (Cara Therapeutics, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Cara Therapeutics, Inc. (CARA) is integrating ESG standards into the synthesis of pruritus medications to reduce chemical waste. This metric measures the annual change in net income per share on a rolling year basis. The indicator's dynamics allow for an assessment of the operating model's efficiency and the pace of capital scaling. Retrospective analysis helps identify the fading of fundamental momentum in a timely manner. The current EPS YoY TTM growth rate on the GURU.Markets platform visualizes this trend.